Corey Langer, MD
Hematology & Oncology · Philadelphia, PANPI 1811918501
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $306,150 of the $492,257 with a category attached, or 62.2%. 37 manufacturers reported payments, led by Merck at 32.7% of the total. Reporting peaked in 2019 at $118,255 and has fallen 51.8% since, to $56,995 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $1491.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$161K
- AstraZeneca$70K
- Takeda Pharmaceuticals U.S.A., Inc.$31K
- Novocure Inc.$28K
- Sanofi$23K
- GSK$20K
- plus $160K from 31 others
Across 117 payments — averaging $61,295 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.2M
- Amgen$2.6M
- Incyte Corporation$904K
- Takeda Pharmaceuticals U.S.A., Inc.$240K
- Clovis Oncology, Inc.$99K
- Novocure Inc.$41K
- plus $70K from 3 others
What the payments were for
- Consulting fees$306,15062%
- Speaking & faculty fees$91,38819%
- Travel & lodging$84,38917%
- Food & beverage$9,3062%
- Education$1,0240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 92 | $160,950 |
| AstraZeneca | 36 | $69,989 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $30,538 |
| Novocure Inc. | 17 | $27,530 |
| Sanofi | 7 | $23,365 |
| GSK | 4 | $19,750 |
| Catalyst Pharmaceuticals, Inc. | 6 | $15,622 |
| Amgen | 7 | $12,200 |
| Jazz Pharmaceuticals Inc. | 16 | $11,703 |
| Astrazeneca UK Limited | 13 | $10,854 |
| Gilead | 12 | $10,358 |
| Genentech USA, Inc. | 21 | $10,269 |
| Lilly USA, LLC | 4 | $9,721 |
| Boehringer Ingelheim | 2 | $8,140 |
| Pfizer | 2 | $7,400 |
| Novartis | 6 | $7,143 |
| Daiichi Sankyo Inc. | 7 | $6,385 |
| Regeneron Healthcare Solutions, Inc. | 13 | $6,341 |
| Johnson & Johnson | 10 | $6,265 |
| Dr.reddy's Laboratories,inc. | 1 | $5,000 |
| Eli Lilly | 2 | $4,375 |
| Janssen Scientific Affairs, LLC | 3 | $4,053 |
| Janssen Research & Development, LLC | 4 | $3,900 |
| G1 Therapeutics, Inc. | 1 | $3,480 |
| Eisai Inc. | 1 | $3,420 |
| Regeneron | 5 | $3,032 |
| Blueprint Medicines Corporation | 1 | $2,156 |
| Taiho Oncology, Inc. | 2 | $2,084 |
| Genentech, Inc. | 1 | $1,980 |
| Exelixis Inc. | 3 | $1,980 |
| Varian Medical Systems, Inc. | 1 | $1,200 |
| EMD Serono, Inc. | 1 | $500 |
| Fosun Pharma USA Inc. | 1 | $181 |
| Bayer | 2 | $173 |
| Mirati Therapeutics, Inc. | 1 | $155 |
| Foundation Medicine, Inc. | 1 | $49 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$35,710
- KEYTRUDA$33,664
- IMFINZI$24,203
- ALUNBRIG$22,388
- LIBTAYO$16,323
- FIRDAPSE$15,500
- ZEPZELCA$11,270
- RYBREVANT$9,911
- TECENTRIQ$9,310
- Enhertu$8,335
- Alecensa$7,179
- MEKINIST$7,046
- TAFINLAR$7,046
- XALKORI$5,600
- ALIMTA$5,250
- LUMAKRAS$4,802
- OPTUNE LUA (NOVOTTF-200T)$3,704
- COSELA$3,480
- LENVIMA$3,420
- IMDELLTRA (AMG 757)$2,058
How this compares
$492,257 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 27 | $642 |
| Prednisone | 71 | $559 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $224 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $177 |
| Azithromycin | 25 | $128 |
| Methylprednisolone | 21 | $120 |
| Alprazolam | 11 | $108 |
| Ondansetron Hcl | 19 | $104 |
| Gabapentin | 16 | $77 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
- Pierluigi PorcuPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.